The KL-6 levels have been reported to correlate with responses to nintedanib in IPF patients, since they decrease during treatment and, in the case of KL-6 levels, they declined during treatment and were associated with pulmonary function test performance [107]. The gene discussed is MUC1; the disease is idiopathic pulmonary fibrosis.